BeStock  
Stocks › Biotechnology › ABCL

AbCellera Biologics ABCL

US equityMarket cap rank #2395BiotechnologyAI medical concept stocks
$9.69 −$0.78 (-7.45%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.73 +0.41%
Open$10.14
Prev close$10.47
Day range$9.58 – $10.26
Volume4.25M
Market cap$3.16B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-23.9x
CheapRich

Near the bottom of its 5-year range · 6th percentile, 5-year average -3.6x

Price / book3.5x
CheapRich

Near the top of its 5-year range · 92nd percentile, 5-year average 1.7x

#3973 of 5331 stocks by PB (1 = cheapest)

Price / sales55.3x
CheapRich

Near the top of its 5-year range · 95th percentile, 5-year average 22.4x

#4884 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-47x-22x2x27xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$15.18
Price vs. fair value-36.2%Trading below the estimate
Star rating★★★★☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 3.53 – 1.74 92% (pricier than usual) #3973 of 5331 (1 = cheapest)
PE -23.94 -18.72 -3.60 6% (cheaper than usual) –
PS 55.31 99.71 22.41 95% (pricier than usual) #4884 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on ABCL.

Sign in to join the discussion.

Scroll to Top